Study Highlights the Economic Power of Health Literacy in Driving India's GDP Growth: The Economist Impact, Supported by Haleon
Business Wire India
A global study released by The Economist Impact , supported by Haleon, reveals that India's healthcare future hinges on one powerful lever: health literacy . The findings of the Health Inclusivity Index , which analyzed 40 countries, looking at groups such as people with low health literacy, people on lower incomes, women, and older adults , highlighted how better access to health information, education, and preventive care can significantly reduce medical costs and boost economic productivity—especially in rapidly developing nations like India.
The Index underlines that underserved groups—such as women, lower-income populations, older adults, and individuals with low health literacy bear the greatest burden of health exclusion. Empowering these communities with evidence-based health solutions is not only a public health imperative but also a powerful economic strategy. The findings also highlight the importance of self-care and health literacy as critical enablers of health inclusion, helping individuals recognize early symptoms, take timely action, and manage everyday health needs more effectively.
Appended are the key findings for India:
1. Oral Health: A Hidden Economic Driver
By managing gum disease effectively in India, $3.5billion could be saved in diabetes-related healthcare costs over the next decade. Poor oral health contributes to $35 billion in productivity losses annually across Index countries, disproportionately affecting low-income populations. Preventive dental care can reduce treatment costs—which are currently nearly 50% higher for underserved groups—by $32.8billion. Targeting lower-income groups could nearly double these savings to over $60 billion.
2. Musculoskeletal Health: Empowering Older Adults and Women
Improving the prevention of musculoskeletal conditions in India among older adults can deliver annual benefits of $1.3billion. Among underserved populations—especially women aged 50 and above—targeted strategies can unlock an additional $2 billion in savings in India. These outcomes demonstrate that inclusive health strategies not only enhance individual well-being but also drive national prosperity.
3. Anaemia and Micronutrient Deficiencies: A Women's Health Crisis
Achieving the UN Sustainable Development Goal of reducing anaemia in women of reproductive age by 50% by 2030 can save $48 billion and reclaim 568 million lost workdays each year across the 40 Index countries. In India alone, reaching this goal can yield $8.7billion in annual benefits. Women, particularly in low- and middle-income countries, bear the highest burden of micronutrient deficiencies, with anaemia rates rising in nearly three-quarters of Index countries.
4. Air Quality: A Public Health and Economic Imperative
Air pollution is a silent driver of chronic illness and lost productivity, particularly in underserved communities. Meeting WHO air quality guidelines can save 4.5 million lives globally and deliver $11.8 billion in annual economic benefits in India alone. The Health Inclusivity Index highlights how reducing air pollution can ease pressure on healthcare systems and unlock major gains for both public health and the economy.
Vedika Kapoor, Head, Communications & Government Affairs, Haleon India Subcontinent, said, 'The Health Inclusivity Index, developed by Economist Impact with support from Haleon, shows that inclusive health is a powerful investment. This third phase reveals that such investments can unlock hundreds of billions in healthcare savings, boost GDP, and prevent millions of deaths annually. Through purpose-led brands like Sensodyne and Centrum, Haleon India is committed to bridging health gaps by promoting self-care behaviours that drive greater inclusion. We urge governments, businesses, and healthcare leaders to unite in building a truly inclusive health ecosystem.'
Link to the full report: https://impact.economist.com/projects/health-inclusivity-index/
The Index builds on two previous phases of research that exposed global gaps in health policy, and the lived experience of health exclusion. Promoting health inclusivity and removing barriers to quality healthcare ensures better health outcomes for everyone, regardless of their circumstances.
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 days ago
- Business Upturn
Merck Foundation Together with African and Asian First Ladies Mark ‘World Assisted Reproductive Technology Day' 2025 Through Their ‘More Than a Mother' Campaign
Merck Foundation , the philanthropic arm of Merck KGaA Germany, marks 'World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors of 'Merck Foundation More Than a Mother' Campaign, by building and advancing fertility care capacity in Africa and Asia. Business Wire India Merck Foundation has made history by training the first local Embryologists and Reproductive & Fertility Experts in many countries such as The Gambia, Liberia, Burundi, Guinea, Chad, Niger, Sierra Leone, Malawi, and Congo. Moreover, supported training for the staff of First Public IVF Centers in Rwanda, Burundi, Ethiopia, Niger, Bangladesh, and Myanmar. Merck Foundation launched 'More Than a Mother Animation Film' that raises awareness about breaking infertility stigma, infertility prevention and male infertility, watch here: Merck Foundation , the philanthropic arm of Merck KGaA Germany, marks 'World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors of 'Merck Foundation More Than a Mother' Campaign, by building and advancing fertility care capacity in Africa and Asia. Senator, Dr. Rasha Kelej, CEO of Merck Foundation and President of 'More Than a Mother' emphasized, "At Merck Foundation we mark World Assisted Reproductive Technology Day by building Fertility and Reproductive Care capacity and empowering infertile women by improving their access to information, change of mindset and quality & equitable fertility care across Africa & Asia as part of our 'More than a Mother' campaign. I am very proud to share that we have provided till today 716 scholarships of Embryology, Fertility and Sexual & Reproductive care to young doctors from 41 countries in Africa and Asia to be the local Embryologists, Fertility & Reproductive care experts in their countries. Moreover, many of our Alumni were trained to be the first local experts in their countries where they never had even a single local embryologist or fertility specialist before our program such as; The Gambia, Burundi, Guinea, Chad, Niger, Sierra Leone, Liberia, Malawi, Congo, Mozambique and more. Together with African First Ladies, and other important partners, we are making history and reshaping the landscape of fertility & Reproductive care across Africa and beyond,' added Dr. Kelej. Merck Foundation 'More Than a Mother' is a powerful campaign that defines interventions to build quality and equitable Reproductive and Fertility Care Capacity, Break Infertility Stigma and Raise Awareness about Infertility Prevention and Male Infertility. Merck Foundation has provided 2280 scholarships for doctors from 52 countries in 44 critical and underserved medical specialties. 'To give an overview, out of our total 716 scholarships for Fertility and Reproductive care, we have provided more than 324 Scholarships for clinical and practical training to Fertility Specialists and Embryologists, and more than 392 Scholarships for PG Diploma and Master Degree in Sexual and Reproductive Medicine, Clinical Psychiatry, Women's Health, Biotechnology of Human Assisted Reproduction & Embryology, Urology, Laparoscopic Surgical skills and Family Medicine to doctors from 41 countries across Africa and Asia. We are proud of this achievement,' added Dr. Rasha Kelej. According to WHO data, more than 180 million couples in developing countries – that is 1 in every 4 couple, suffer from infertility. In many cultures in Africa, infertility is a huge stigma. Women are solely blamed for failing to conceive and the social stigma of childlessness, especially for women leads to isolation and stigmatization and results in discrimination and ostracism. This mostly also leads to divorce or physical or psychological violence. As a part of 'More Than a Mother' Campaign, Merck Foundation has launched many initiatives to break this stigma and create a culture shift. Merck Foundation has also been empowering childless and infertile women through their 'Empowering Berna' initiative under their 'More Than a Mother' movement. This initiative helps women who cannot be treated for infertility anymore by helping them get trained to establish small businesses so that they can be independent and rebuild their lives. Through 'Empowering Berna', the lives of many infertile women have been transformed in many African countries like Kenya, Uganda, Nigeria, Central African Republic, Niger, Malawi, and many more. 'It's all about giving every woman the respect and the help she deserves to lead a fulfilling life, with or without a child,' added Dr. Kelej. Moreover, Merck Foundation has trained more than 3700 media representatives from more than 35 countries to raise community awareness and break the stigma around infertility and infertile and childless women. Merck Foundation in partnership with Africa's First Ladies, has also launched 'More Than Mother' Children's storybook to emphasize strong family values of love and respect from a young age which will reflect on eliminating the stigma of infertility and the resulted domestic violence in the future. The storybooks have been localized for each country and in three languages, English, French and Portuguese to better connect with the young readers. The book has also been adapted to an animation film. Watch More Than a Mother Animation Film here: Merck Foundation's pan African TV program 'Our Africa', that is conceptualized, produced, directed, and co-hosted by Senator, Dr. Rasha Kelej, CEO of Merck Foundation and features African Fashion Designers, Singers, and prominent experts from various domains with the aim to raise awareness and create a culture shift across Africa, has many episodes dedicated to raise awareness about infertility and breaking infertility stigma. Watch the episodes here: Episode 3: Episode 5: Episode 10: Merck Foundation has also released about 30 songs, many of these songs have been created with the aim to break the infertility stigma, as a part of their 'More Than a Mother' campaign. Listen to some of the songs here: Watch, share & subscribe to the 'Plus qu'une MERE' composed and sung by Ms. Lucky-Lou, the daughter of The President and The First Lady of Burundi: Watch, share & subscribe to the 'More Than a Mother' song by Cwesi Oteng and Adina from Ghana: Watch, share & subscribe to the 'More Than a Mother' song by Zambian Soul Singer Wezi: Watch, share & subscribe to the 'More Than a Mother' song by Sunita Daffeh from the Gambia: Listen to all 'More than a Mother' songs here: 'To address this important issue of breaking infertility stigma and also a wide range of other social issues, we annually launch Merck Foundation 'More Than a Mother' Awards in partnership with African First Ladies. I would also like to invite the African Community of Media, Fashion, Filmmaking, and Musicians, students, and potential talents in these fields to apply for the awards this year by sharing their creative work on [email protected] , ' concluded Senator, Dr. Rasha Kelej. Click on the link below to Download Merck Foundation App Join the conversation on our social media platforms below and let your voice be heard! Facebook: Merck Foundation X: @MerckFoundation YouTube: MerckFoundation Instagram: Merck Foundation Threads: Merck Foundation Flickr: Merck Foundation Website:
Business Upturn
5 days ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
7 days ago
- Business Upturn
Study Highlights the Economic Power of Health Literacy in Driving India's GDP Growth: The Economist Impact, Supported by Haleon
A global study released by The Economist Impact, supported by Haleon, reveals that India's healthcare future hinges on one powerful lever: health literacy. The findings of the Health Inclusivity Index, which analyzed 40 countries, looking at groups such as people with low health literacy, people on lower incomes, women, and older adults , highlighted how better access to health information, education, and preventive care can significantly reduce medical costs and boost economic productivity—especially in rapidly developing nations like India. Business Wire India A global study released by The Economist Impact , supported by Haleon, reveals that India's healthcare future hinges on one powerful lever: health literacy . The findings of the Health Inclusivity Index , which analyzed 40 countries, looking at groups such as people with low health literacy, people on lower incomes, women, and older adults , highlighted how better access to health information, education, and preventive care can significantly reduce medical costs and boost economic productivity—especially in rapidly developing nations like India. The Index underlines that underserved groups—such as women, lower-income populations, older adults, and individuals with low health literacy bear the greatest burden of health exclusion. Empowering these communities with evidence-based health solutions is not only a public health imperative but also a powerful economic strategy. The findings also highlight the importance of self-care and health literacy as critical enablers of health inclusion, helping individuals recognize early symptoms, take timely action, and manage everyday health needs more effectively. Appended are the key findings for India: 1. Oral Health: A Hidden Economic Driver By managing gum disease effectively in India, $3.5billion could be saved in diabetes-related healthcare costs over the next decade. Poor oral health contributes to $35 billion in productivity losses annually across Index countries, disproportionately affecting low-income populations. Preventive dental care can reduce treatment costs—which are currently nearly 50% higher for underserved groups—by $32.8billion. Targeting lower-income groups could nearly double these savings to over $60 billion. 2. Musculoskeletal Health: Empowering Older Adults and Women Improving the prevention of musculoskeletal conditions in India among older adults can deliver annual benefits of $1.3billion. Among underserved populations—especially women aged 50 and above—targeted strategies can unlock an additional $2 billion in savings in India. These outcomes demonstrate that inclusive health strategies not only enhance individual well-being but also drive national prosperity. 3. Anaemia and Micronutrient Deficiencies: A Women's Health Crisis Achieving the UN Sustainable Development Goal of reducing anaemia in women of reproductive age by 50% by 2030 can save $48 billion and reclaim 568 million lost workdays each year across the 40 Index countries. In India alone, reaching this goal can yield $8.7billion in annual benefits. Women, particularly in low- and middle-income countries, bear the highest burden of micronutrient deficiencies, with anaemia rates rising in nearly three-quarters of Index countries. 4. Air Quality: A Public Health and Economic Imperative Air pollution is a silent driver of chronic illness and lost productivity, particularly in underserved communities. Meeting WHO air quality guidelines can save 4.5 million lives globally and deliver $11.8 billion in annual economic benefits in India alone. The Health Inclusivity Index highlights how reducing air pollution can ease pressure on healthcare systems and unlock major gains for both public health and the economy. Vedika Kapoor, Head, Communications & Government Affairs, Haleon India Subcontinent, said, 'The Health Inclusivity Index, developed by Economist Impact with support from Haleon, shows that inclusive health is a powerful investment. This third phase reveals that such investments can unlock hundreds of billions in healthcare savings, boost GDP, and prevent millions of deaths annually. Through purpose-led brands like Sensodyne and Centrum, Haleon India is committed to bridging health gaps by promoting self-care behaviours that drive greater inclusion. We urge governments, businesses, and healthcare leaders to unite in building a truly inclusive health ecosystem.' Link to the full report: The Index builds on two previous phases of research that exposed global gaps in health policy, and the lived experience of health exclusion. Promoting health inclusivity and removing barriers to quality healthcare ensures better health outcomes for everyone, regardless of their circumstances. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
